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Abstract The range of the biochemical reactions which can be
catalyzed by ADH I and ADH IV is extremely wide. The most
characterized functions of these enzymes are protection against
excess endogenous acetaldehyde, products of lipid peroxidation,
exogenous alcohols and some xenobiotics. It was found also that
ADH I and ADH IV are important members of the enzyme
system synthesizing retinoic acid (especially during embryogen-
esis). They can oxidize some steroids and participate in bioamine
and prostaglandin metabolism but so far the extent of their
contribution to the latter processes is under discussion. Recent
data suggest a correlation between the activity of ADH I in some
organs and fine physiological processes including behavior
regulation and craving for alcohol in albino rats. ß 2000 Fed-
eration of European Biochemical Societies. Published by Else-
vier Science B.V. All rights reserved.
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1. Introduction
There are six known classes of mammalian alcohol dehy-
drogenases (ADH), but only ADH I and ADH IV can be
characterized as principal participants of ethanol metabolism.
It is not surprising that these enzymes are extremely well
studied because the investigation in this area was inspired
by the problem of alcoholism. However, many questions re-
garding ADH I and ADH IV functions still remain: Are
ethanol metabolizing enzymes the protectors or provocators
of alcoholism? What is the overall range of alcohols and
xenobiotics dealing with ADH I and ADH IV? Is the ethanol
metabolizing role of these enzymes their main function? Last
decade brought a lot of new data in this area.
2. Protective functions
The array of protective functions of ADH I and ADH IV is
extremely wide. Ethanol oxidation to acetaldehyde catalyzed
by ADH I and ADH IV in vivo is reversible. Moreover, in the
absence of exogenous ethanol the equilibrium is shifted to-
wards the reduction of endogenous acetaldehyde. Thus
ADH I together with acetaldehyde dehydrogenase play an
important role in controlling the level of this toxic metabolite.
As shown recently, ADH I can also catalyze the dismutation
of acetaldehyde into ethanol and acetate [1]. Along with ace-
taldehyde, ADH I can detoxicate some other endogenous
compounds which may be harmful, e.g. lipid peroxidation
products, such as 4-hydroxyalcenals [2].
Under conditions of high ethanol consumption, the role of
ADH I and ADH IV is particularly important. The ¢rst bar-
rier on the usual way of exogenous ethanol is formed by ADH
IV in stomach and intestine mucosa [3]. The second barrier,
which is the principal one, is formed in liver. There are two
main metabolic pathways that are involved in the oxidation of
exogenous ethanol in liver: ADH I-dependent and cyto-
chrome-dependent pathways. In non-alcoholized animals,
these pathways have about equal importance while after alco-
holization of an animal the chronic metabolic de¢cit of
NAD is created and the role of cytochrome system increases.
ADH I takes part in the metabolic degradation of many
xenobiotics, including numerous aliphatic and cyclic alcohols
and some other toxic compounds widely distributed in a con-
temporary human environment. For example, ADH I is able
to oxidize 1,3-butadiene derivatives, which are toxic and can-
cerogenic products detected in cigarette smoke, gasoline and
used in synthetic rubber manufacture [4].
Considering protective function of ADH I and/or ADH IV,
we have to take into account their very wide distribution in
the organism. Besides liver (90% of total ADH I), consider-
able amounts are in skin, stomach and intestine mucosa. A
signi¢cant pool of these enzymes was found in several endo-
crine organs and blood vessels [5^9].
3. Participation in retinol and steroid metabolism
All data described above characterize the role of ADH I
and ADH IV in protecting the organism from a wide range of
compounds. However, data have accumulated describing the
involvement of ADH I and ADH IV in many reactions which
are not directly related to the protective functions and asso-
ciated with other major biochemical and physiological pro-
cesses.
A special role of ADH I and ADH IV in the synthesis of
retinoic acid and their derivatives was discovered. Retinoic
acid is presently considered to be a hormonal factor, which
is involved not only in vision pathway but also in morpho-
genesis of skin, digestive and respiratory systems, and in cer-
tain processes of immune, nervous and hematopoethic sys-
tems. Retinoids were found to be useful for the treatment of
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certain skin diseases, diabetes and as additional medication
for cancer treatment. All this information inspired a search
for key enzymes of retinol oxidation, which revealed that both
ADH I and ADH IV can e¡ectively catalyze these reactions,
ADH IV being more active [10,11]. Interestingly, these en-
zymes are able to oxidize only free retinol, which is not linked
to speci¢c protein carriers, while bound retinol is oxidized by
a recently described large family of short-chain dehydrogen-
ases/reductases (SDR) [11]. It was shown recently that during
embryogenesis of the adrenal gland, ADH I and ADH IV
play a speci¢c role and their concentration is high on certain
stages. Of note, the adrenal gland was shown to be one of the
main endocrine centers where the intensive synthesis of reti-
noic acid takes place [12]. Skin epithelial cells are also char-
acterized by the ADH IV- and/or ADH I-dependent synthesis
of retinoic acid [7,13]. Therefore, the existence of SDR does
not depreciate the independent role of ADH I and ADH IV in
retinol metabolism. Both families have their speci¢city.
To date, a lot of data which demonstrate the ability of
ADH I to oxidize hydroxysteroids have accumulated [14^
17]. Of note, only the Q-isoenzyme of human ADH I is active
in steroid transformation [17]. However, since SDP (men-
tioned above as alternative enzymes for retinoic acid synthe-
sis) can also catalyze many reactions of hormonal steroid
oxidation, it is not clear whether ADH I or ADH IV plays
the key role in these processes. SDP seem to be more speci¢c
in oxidation of certain hormonal steroids [18^21].
4. Possible participation in neuromediator metabolism
There are certain indications for the ADH I and ADH IV
participation in the metabolism of several neuromediators and
prostaglandins. ADH I e¡ectively catalyzes in vitro the trans-
formations of several alcohols and aldehydes which are
involved in the metabolism of dopamine: 3,4-dihydroxy-
phenylethanol, 4-hydroxy-3-methoxyphenylethanol and corre-
sponding aldehydes (ADH II and ADH III do not have such
an activity) [22]. ADH I also oxidizes some glycols, which
take part in norepinephrine metabolism, but in this case
ADH I is less active by comparison with ADH II [23].
ADH I can also catalyze the oxidation of serotonin catabolite,
5-hydroxytryptophol [24]. These data are potentially interest-
ing concerning the suggestion described below about ADH I
involvement in the regulation of craving for ethanol. How-
ever, it is not clear yet how important these reactions are in
catecholamine and serotonin metabolism in vivo: they can
represent some collateral metabolic pathways.
5. Putative role in craving for ethanol
There are certain indications for indirect involvement of
ADH I and ADH IV activity in the highest physiological
processes, behavior regulation and craving for ethanol in par-
ticular. ADH I is not found in brain, so the only way it can
a¡ect the central nervous system is the penetration of the
products of ADH I activity through the blood-brain barrier.
However, some contradictions exist considering the behavi-
oral activity of ADH I main product, acetaldehyde. A lot of
data obtained on di¡erent human races and populations show
that fast accumulation of acetaldehyde forced by the partic-
ularly active ADH I isozymes and under reduced activity of
acetaldehyde dehydrogenase cause aversive behavioral reac-
tions to ethanol. Potent ADH I inhibitor cimetidine (well
known antiulcer drug) provokes ethanol consumption [25].
Therefore high ADH I activity seems to be a defensive factor
against alcoholism development. Surprisingly, not all ADH I
inhibitors increase the craving to alcohol. On the contrary,
some of them (e.g. metronidazole) reduce alcohol motivation
[26]. As this latter inhibitor could a¡ect the craving for alco-
hol through some other mechanisms, autoantibodies to ADH
I were used to reveal ADH I role [27^29]. The autoantibodies
were produced in albino rats, immunized by horse liver ADH
I. The autoantibodies decreased the ADH I activity in liver
and blood vessels, but a particularly signi¢cant decrease of
enzyme activity was observed in adrenal medulla. A reliable
long-term decrease of rat craving for ethanol was demon-
strated. The e¡ect was quite speci¢c, since similar decrease
in alcohol motivation was demonstrated in rats after the ad-
ministration of antibodies to an ADH epitope
(S265FFVIGRLDTMV276) or after active immunization using
conjugates of this peptide with an antigen carrier. This phe-
nomenon may have two explanations: the decrease in ADH I
activity reduces the acetaldehyde/ethanol ratio or a¡ects other
reactions involving ADH I. The ¢rst explanation is not very
likely since acetaldehyde is well known to be a factor sup-
pressing the craving for ethanol, thus decreasing its concen-
tration can even have an opposite e¡ect. The second explan-
ation is in accordance with the ADH I role in the synthesis of
retinoic acid, hormone steroids and some neuromediators.
Interestingly, one of the most characterized ADH I activities,
the oxidation of retinol, is located in adrenal glands, where
the most signi¢cant ADH I suppression in experiments with
autoantibodies was observed. Changes in neuromediator and
steroid concentration associated with ADH I are also possi-
ble. However, for the moment all these suggestions are ex-
tremely speculative because of insu⁄cient data, and the
most illuminating result would be revealing the situation
when ADH I acts as provocator of craving for ethanol.
Fig. 1. Di¡erent ways of in£uence of ADH I and/or ADH IV activ-
ity on craving for ethanol.
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6. Conclusion and perspectives
To summarize, there are several di¡erent manifestations of
major biochemical and physiological functions of ADH I and
ADH IV (Fig. 1): (1) defence against exogenous alcohols and
some xenobiotics, detoxication of endogenous acetaldehyde
and lipid peroxidation, (2) role in retinol oxidation, particu-
larly during embryogenesis of adrenal glands and skin, (3)
contribution to hydroxysteroids oxidation, (4) possible in-
volvement in neuromediator metabolism, (5) e¡ects on crav-
ing for ethanol. The phenomenon of long-term suppression of
craving for ethanol after induction of autoantibodies to ADH
I seems to be particularly interesting for the study of the
molecular mechanism of alcoholism. Further investigation of
the distribution of functions between short-chain dehydrogen-
ases/reductases, ADH I and ADH IV is promising for better
understanding their role in hormonal and neuromediator reg-
ulation.
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